Kihealth Europe
Pipeline

One platform. One disease area. Real metabolic leverage in Europe.

Kihealth Europe is exclusively focused on metabolic disease. Intercept IQ™ is the foundational platform; BetaIntercept™ T1D and BetaIntercept™ T2D translate it into programmes for the two diseases that define modern diabetes care.

Foundational Platform

Intercept IQ™

Liquid-biopsy intelligence for metabolic disease

Tissue-resolved cfDNA · methylation · fragmentomics

Phase · Validation78%
Programme context

Intercept IQ™ is the shared molecular substrate behind every BetaIntercept™ programme — built around ultra-deep cell-free DNA sequencing, beta-cell-specific methylation signatures and machine-learned tissue-of-origin inference.

Milestone history
  1. 2023Beta-cell methylation atlas locked
  2. 2024Analytical validation across European reference cohorts
  3. 2026Clinical-grade pipeline release and external benchmarking
Next milestone

Cross-cohort analytical lock and clinical-grade pipeline release

Type 1 Diabetes

BetaIntercept™ T1D

Beta-cell injury and loss in Type 1 Diabetes

Beta-cell unmethylated INS cfDNA

Phase · Clinical Studies72%
Programme context

Designed to evaluate active beta-cell destruction across Stage 1–3 T1D, in support of earlier intervention strategies and the emerging European disease-modifying therapy landscape.

Milestone history
  1. 2023Analytical validation completed
  2. 2024Prospective paediatric cohort (n≈1,840) read out
  3. 2026European pivotal-style study initiation being planned
Next milestone

European multi-site enrolment expansion

Type 2 Diabetes

BetaIntercept™ T2D

Beta-cell stress, dysfunction and progression in Type 2 Diabetes

Multi-tissue metabolic methylation panel

Phase · Validation54%
Programme context

A multi-tissue panel designed to surface beta-cell stress and dysfunction long before HbA1c moves — supporting research into staging, progression and therapeutic response in Type 2 Diabetes.

Milestone history
  1. 2024Discovery cohort locked
  2. 2025Analytical validation under way
  3. 2026Multi-site European clinical validation being scoped
Next milestone

Multi-site European validation cohort

Forward Programme

Future Metabolic Health Applications

Adjacent metabolic indications powered by the same beta-cell biology

Extended cfDNA + metabolic methylation features

Phase · Discovery22%
Programme context

Forward-looking research extending the Intercept IQ™ platform to additional metabolic conditions where beta-cell biology, insulin signalling and tissue stress provide a measurable liquid-biopsy signal.

Milestone history
  1. 2025Adjacent-indication feasibility scoping
  2. 2026Discovery cohort design with European partners
  3. 2027Selected applications advance to validation
Next milestone

Indication selection and feasibility scoping with European centres

Programme phases and milestones reflect current research and development plans, including activities being investigated through European partnerships. Programmes are research and development efforts and are not authorised for routine clinical diagnosis in the European Union.

Considering co-development, biobank access, or a European clinical site?

Partnership Opportunities Validation Evidence